Market ‘sleeping’ on Teladoc, sees stock rerating higher, says Citron Research

Teledoc (TDOC), which just acquired Catapult Health, is using technology the “right” way, by cutting costs, improving care, and expanding margins, all while making money, Citron Research says in a new note. While telemedicine has slowed, the firm argues that Teledoc is becoming a lean, high margin business that companies like CVS (CVS) or Amazon (AMZN) “would love to own.” Citron believes the market is “sleeping” on Teladoc, and that once the market catches up, the stock should rerate higher.